Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic Squamous Non-Small-Cell Lung Cancer (US/EU)
With only a small percentage of patients harboring a biomarker-driven metastatic squamous non-small-cell lung cancer (NSCLC) (about 10% of all patients in the G7 countries), the preferred first-…
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The treatment landscape for advanced HR-positive / HER2-negative breast cancer is continually evolving. CDK4/6 inhibitors, such as Pfizer’s Ibrance and Novartis’s Kisqali, are commonly used…
Renal Cell Carcinoma – Unmet Need – Unmet Need – Advanced or Metastatic Renal Cell Carcinoma (US/EU)
The treatment of advanced or metastatic renal cell carcinoma is dominated by immune checkpoint inhibitors (e.g., Merck & Co.’s Keytruda, BMS’s Opdivo and Yervoy) and small-molecule tyrosine…
Gastroesophageal Cancer – Unmet Need – Unmet Need – Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (US/EU)
Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease…
Pancreatic Cancer – Unmet Need – Unmet Need – Locally Advanced or Metastatic Pancreatic Adenocarcinoma (US/EU)
Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic…
Bladder Cancer and Upper Tract Urothelial Carcinoma – Geographic Focus: China – Bladder Cancer and Upper Tract Urothelial Carcinoma | China In-Depth (China)
Bladder cancer is the eighth most diagnosed kind of cancer in China. The bladder cancer therapy market will experience rapid growth over the forecast period, fueled by one of the most robust drug-…
